Table 2

Characteristics of methotrexate (MTX) treated rheumatoid arthritis (RA) patients and of RA controls who developed cancers

Patient Cancer Agea Sex RA duration (years) Sjögren syndrome Treatment Evolution of cancer Follow upb (months)
1melanoma62F30-surgeryremission50
2lungc 66M9+surgerydeath-
3NHLd 66F14+chemotherapyremission71
4Hodgkin56M4.5-radio- + chemotherapyremisssion65
5gastrice 69M4+surgerydeath-
6cervix44F21-radiotherapy + surgeryremission33
7womb46F1+surgeryremission24
8Paget of breast56F4-radiotherapy + surgeryremission47
9cervix38F20-surgeryremission66
10NHL37F19+chemotherapyrecurrence60
11prostatic68M10-surgery +
hormone therapy
lostg -
12CMLf 70F21+chemotherapydeath14
13Waldenström79F10+corticosteroidsremission36
14gastric69F3-surgerylostg -
  • Patients 1 to 8: MTX treated patients; patients 9 to 14: control patients; aage at diagnosis of cancer;bafter diagnosis of cancer; ctobacco abuse, 50 pack-years; dnon-Hodgkin lymphoma, centroblastic, centrocytic follicular, in lymph nodes and thyroid, with Hashimoto thyroiditis; e10 years before, 2/3 gastrectomy for peptic ulcer; fchronic myeloid leukemia; g lost to follow up